By Dr. Michel Daher, PharmD, RPh, APHEditor's Note: This article was originally published in Februar
redstate.com Editor’s Note: This article was originally published in February, but given the renewed interest in and discussions regarding tariffs, we thought it worth a revisit.
In late January, it was announced the Trump administration would begin to tariff Canada and Mexico due to perceived trade deficits. President Donald Trump also mentioned possible tariffs on China for the amount of Fentanyl that pours into the country through the southern border. I have had the opportunity to write for RedState on many topics in the pharmacy world, but with the possibility of new tariffs comes an opportunity for us as Americans.
As many patients on medications know, drugs come in a “brand name” or “generic” form. The brand name drug gets a patent by the pharmaceutical industry and has about 12 years to capitalize on its success. Many drugs do not make it to market. At the end of the patent come the lawsuits to keep it a “brand” name as long as possible. Once the patent expires, everyone gets access to the ingredients and can then begin to produce it as a “generic name.” The FDA states that as long as the active ingredient is “80-125%” of the brand name, it can be therapeutically equivalent. This is interesting, especially when some patients state, “The generic doesn’t work for me”… and that is a topic for another time.
…
Read Full Article Here…(redstate.com)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
